Meta-analysis of seven phase 2 trials shows metastasis-directed therapy plus standard care significantly improves progression-free survival and other endpoints in oligometastatic prostate cancer patients, with a near-significant trend toward improved overall survival.
Recent studies demonstrate high response rates for antibody-drug conjugate in rare blood cancer, improved outcomes with metastasis-directed radiation in prostate cancer, and a novel drug combination strategy for ovarian cancer resistance.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07490210 |
Rezvilutamide With Radical Prostatectomy and Metastasis-Directed Therapy in Oligometastatic Prostate Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07015138 |
Comprehensive Versus Primary Tumor Radiotherapy in Oligometastatic Prostate Cancer |
RECRUITING | NA |
| NCT06972511 |
Maximal Tumor Eradication for Oligometastatic Prostate Cancer |
RECRUITING | PHASE2/PHASE3 |
| NCT06387056 |
Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO) |
RECRUITING | PHASE2 |
| NCT06060652 |
Prostate Oligometastatic Cancer Management Driven by Disease Biology et/or Immunoactivity (PROMETEO) |
RECRUITING | |
| NCT05915442 |
Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer |
RECRUITING | PHASE2 |
| NCT05560659 |
Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative Radiotherapy |
RECRUITING | PHASE2 |
| NCT04992026 |
The Efficacy and Safety of Prostatectomy for Castration-Naive Oligometastatic Prostate Cancer |
COMPLETED | PHASE2 |
| NCT04610372 |
5500/20 vs. SABR or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment (PROMPT) |
RECRUITING | NA |
| NCT03940235 |
Radioablation With or Without Androgen DeprIvation Therapy in Metachronous Prostate Cancer OligometaStAsis |
UNKNOWN | PHASE2 |
